The Evolution of HIV/AIDS Therapies:
Since its emergence as a global epidemic 30 years ago, HIV/AIDS has been transformed from a fatal illness into a manageable chronic disease owing to the powerful antiretroviral therapies discovered and developed by chemists, virologists, clinicians, and many others working together at academic, government, and biopharmaceutical industry laboratories around the world.
On December 4, 2012, CHF presented a conversation focusing on the fascinating story of chemical innovation underlying the development of effective treatments along with their global impact.
The event, moderated by Jeffrey Sturchio, engaged four luminaries in HIV/AIDS research, policy, and practice—Gregg Alton and Norbert Bischofberger from Gilead Sciences, and Sir Richard Feachem and Paul Volberding from the University of California, San Francisco—in a conversation about both the remarkable progress we have seen in HIV therapies and the challenges still to be met.
Watch an edited video of The Evolution of HIV/AIDS Therapies: A Conversation below.
The Evolution of HIV/AIDS Therapies from ChemHeritage on Vimeo.
Edward E. Penhoet, Director, Alta Partners
Jeffrey L. Sturchio, Senior Partner, Rabin Martin
- Gregg H. Alton, Executive Vice President, Corporate and Medical Affairs at Gilead Sciences
- Norbert W. Bischofberger, Executive Vice President, Research and Development, and Chief Scientific Officer, Gilead Sciences
- Sir Richard G. A. Feachem, Professor of Global Health, University of California, San Francisco and Berkeley; Director, Global Health Group, UCSF Global Health Sciences; and Founding Executive Director, The Global Fund to Fight AIDS, TB, and Malaria
- Paul A. Volberding, Professor, Department of Medicine; Director, AIDS Research Institute; Director of Research, Global Health Sciences; and Codirector, Center for AIDS Research, University of California, San Francisco
On October 28, 2014, CHF's sixth annual T. T. Chao Symposium on Innovation posed the question, "Can We Meet the Challenge of HIV/AIDS?" Since the disease was first described in 1981, remarkable progress has been made in fighting it. This symposium addressed how progress has changed our approach to research and health policy, with a panel discussion and presentations by leading figures including José Esparza and Robert C. Gallo.